Diabetes Research and Clinical Practice
Volume 72, Issue 1 , Pages 81-87 , April 2006

Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients

  • Jonathan Sorof

      Affiliations

    • Cardiovascular Clinical Research, AstraZeneca LP, C4B-717, 1800 Concord Pike, Wilmington, DE 19803, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 302 885 0250; fax: +1 302 885 5450.
    • ,
  • Christian Berne

      Affiliations

    • Medicinkliniken, Akademiska Sjukhuset, Uppsala, Sweden
    • ,
  • Annica Siewert-Delle

      Affiliations

    • AstraZeneca, Södertälje, Sweden
    • ,
  • Leif Jørgensen

      Affiliations

    • AstraZeneca, Södertälje, Sweden
    • ,
  • Philip Sager

      Affiliations

    • Cardiovascular Clinical Research, AstraZeneca LP, C4B-717, 1800 Concord Pike, Wilmington, DE 19803, USA
    • ,
  • on behalf of the URANUS study investigators

Received 27 June 2005 ,Revised 26 August 2005 ,Accepted 2 September 2005.

References 

  1. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care. 2004;27:1798–1811
  2. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J. Intern. Med. 2001;249:225–235
  3. Grundy SM, Cleeman JI, Merz CN, Brewer HBJ, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  4. Bocan TM. Pleiotropic effects of HMG-CoA reductase inhibitors. Curr. Opin. Investig. Drugs. 2002;3:1312–1317
  5. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann. Intern. Med. 2004;140:650–658
  6. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  7. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004;350:1495–1504
  8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Final report, Circulation 106 (2002) 3143–3421.
  9. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am. J. Kidney Dis. 1999;34:795–808
  10. Verhulst A, D’Haese PC, De Broe ME. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J. Am. Soc. Nephrol. 2004;15:2249–2257
  11. Sidaway JE, Davidson RG, McTaggart F, Orton TC, Scott RC, Smith GJ, et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J. Am. Soc. Nephrol. 2004;15:2258–2265
  12. Berne C, Siewert-Delle A URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc. Diabetol. 2005;4:7
  13. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Atherosclerosis. 1998;140:199–270
  14. Fabiny DL, Ertingshausen G. Automated reaction-rate method for determination of serum creatinine with the CentrifiChem. Clin. Chem. 1971;17:696–700
  15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999;130:461–470
  16. Lehmann EL. Nonparametric Statistical Methods Based on Ranks. New York: McGraw-Hill; 1975;
  17. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology. 2004;102:52–60
  18. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension. 2002;40:67–73
  19. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am. J. Kidney Dis. 2003;41:565–570
  20. Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care. 1997;20:1891–1895
  21. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur. J. Clin. Invest. 2000;30:980–987
  22. Hommel E, Andersen P, Gall MA, Nielsen F, Jensen B, Rossing P, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia. 1992;35:447–451
  23. Vervoort G, Willems HL, Wetzels JF. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol. Dial. Transplant. 2002;17:1909–1913

PII: S0168-8227(05)00368-2

doi: 10.1016/j.diabres.2005.09.004

Diabetes Research and Clinical Practice
Volume 72, Issue 1 , Pages 81-87 , April 2006

Article Tools

* Image Usage & Resolution